vTv Therapeutics Inc. reports developments as a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a liver-selective glucokinase activator being investigated as an oral adjunctive therapy to insulin for type 1 diabetes. Company updates also reference development work and partnerships across additional chronic-disease candidates, including the PDE4 inhibitor HPP737.
Recurring announcements include clinical and regulatory updates for cadisegliatin, financial results and corporate updates, license and collaboration activity, investor-conference participation, and Nasdaq inducement grants under equity compensation plans. News about vTv often connects pipeline progress with funding arrangements, intellectual property, and business-development agreements that support its drug-development strategy.
vTv Therapeutics (Nasdaq: VTVT) reported third-quarter financial results and completed enrollment of 166 participants in its Phase 3 CATT1 trial. The study evaluates cadisegliatin alongside insulin for type 1 diabetes; vTv expects topline results in mid 2027. The first participant was also randomized in the Phase 2a Hybrid CATT1 study for people using hybrid closed-loop insulin delivery systems. HPPD received FDA Orphan Drug Designation for sickle cell disease.
Third-quarter net loss attributable to shareholders widened to $11.620 million from $8.698 million a year earlier, while loss per share narrowed to $0.94 from $1.08. Cash totaled $77.164 million at September 30, versus $88.932 million at December 31, 2025. vTv expects its cash to fund operations well through the anticipated CATT1 readout. Nine-month revenue was $36.839 million, versus none a year earlier.
vTv Therapeutics (VTVT) randomized the first participant in its Phase 2a Hybrid CATT1 pilot study of cadisegliatin in type 1 diabetes. The study evaluates the investigational oral drug alongside insulin in adults using hybrid closed-loop systems, which automate some insulin delivery but still require user input.
The double-blind, placebo-controlled, two-way crossover study is expected to enroll approximately 40 adults. Its primary objective is to assess glucose-monitor-based measures of blood sugar control, including time within a target range, after six weeks of treatment. Standardized meal tests will assess blood sugar changes after meals. The company expects the pilot to inform future Phase 3 research in this population. Enrollment in the separate Phase 3 CATT1 study, limited to participants using insulin pens or open-loop pumps, was completed earlier this month.
vTv Therapeutics (VTVT) presented research on hypoglycemia-related burdens among adults using automated insulin delivery systems at the Breakthrough T1D Clinical & Research Congress.
The company-commissioned online survey, conducted by dQ&A Market Research, included 674 adults with type 1 diabetes, including 429 using automated insulin delivery. Among these users, 24% reported frequent Level 2 hypoglycemia, involving glucose below 54 mg/dL; 12% reported a Level 3 event in the past 12 months; and 17% reported rarely or never noticing hypoglycemia symptoms. Among those with A1C above 7%, 49% strongly agreed they keep glucose higher to avoid hypoglycemia or would target lower levels without that risk. After accounting for overlapping responses and weighting for A1C, approximately 54% of adult users were estimated to experience at least one of the four burden dimensions.
vTv Therapeutics (Nasdaq: VTVT) received FDA Orphan Drug Designation for HPPD, its investigational oral treatment for sickle cell disease.
Preclinical studies at Augusta University used the Townes sickle cell disease mouse model. HPPD was orally active and well tolerated, increased fetal hemoglobin, and reduced oxidative stress and red blood cell sickling. Fetal hemoglobin increases were time- and dose-dependent, with effects comparable to or exceeding hydroxyurea, the current standard fetal hemoglobin-inducing therapy.
vTv said the designation supports partnering discussions for HPPD while it continues to prioritize cadisegliatin, its lead late-stage type 1 diabetes program. HPPD remains investigational; its safety and efficacy have not been established, and approval or commercial availability is not guaranteed.
vTv Therapeutics (VTVT) will host a virtual expert event on hypoglycemia and its cadisegliatin Phase 3 program on October 20, 2026.
The event starts at 2:30 PM ET and covers type 1 diabetes treatment challenges and the ongoing CATT1 trial, which evaluates cadisegliatin as an oral therapy added to insulin. The company expects topline data in mid 2027. A live question-and-answer session will follow, with a replay available on the company's Investor Relations website.
vTv Therapeutics (VTVT) has completed enrollment in its Phase 3 CATT1 study of cadisegliatin as an adjunct to insulin for type 1 diabetes. The study randomized 166 patients, and the company expects topline results in mid 2027. Cadisegliatin has received FDA Breakthrough Therapy designation for this use.
The randomized, double-blind, placebo-controlled study evaluates efficacy and safety over six months in adults using insulin injections or infusion alongside continuous glucose monitoring. Participants receive cadisegliatin 800 mg once daily, 800 mg twice daily, or placebo. The primary endpoint measures the incidence of level 2 and level 3 hypoglycemic events, episodes of low blood sugar. Secondary endpoints include changes in HbA1c, a measure of blood sugar control, time in target glucose range, and diabetic ketoacidosis incidence compared with placebo. Cadisegliatin remains investigational; its safety and efficacy have not been established.
vTv Therapeutics (VTVT) granted stock options to purchase 2,500 shares of common stock to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $31.44 per share, a 10-year term, and vest over 4 years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting quarterly over the following 36 months, subject to continued employment. The grant is made under the company’s 2026 Inducement Plan and a related stock option agreement. vTv is a late-stage biopharmaceutical company whose lead candidate, cadisegliatin (TTP399), is in a US Phase 3 trial for type 1 diabetes and has FDA Breakthrough Therapy designation.
vTv Therapeutics (VTVT) will participate in two investor conferences in September 2026 to discuss its late-stage work on cadisegliatin, an oral investigational therapy for type 1 diabetes. Management will join a fireside chat and one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 16 in New York and hold one-on-one investor meetings at the 5th Annual ROTH Healthcare Opportunities Conference on September 29.
vTv Therapeutics (Nasdaq: VTVT) granted 2,500 stock options to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.48 per share, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting quarterly over the next 36 months, subject to continued employment.
The grant is made under the company’s 2026 Inducement Plan. vTv is a late-stage biopharmaceutical company whose clinical pipeline is led by cadisegliatin (TTP399), an oral glucokinase activator in a US Phase 3 trial for type 1 diabetes and granted FDA Breakthrough Therapy designation.
vTv Therapeutics (Nasdaq: VTVT) reported second quarter 2026 results and a corporate update centered on cadisegliatin for type 1 diabetes (T1D). Enrollment in the Phase 3 CATT1 trial, evaluating cadisegliatin as an oral adjunctive therapy to insulin, is expected to complete in the third quarter of 2026. A Phase 2a Hybrid CATT1 trial in T1D patients using hybrid closed-loop insulin delivery is expected to initiate before year end 2026, and a KOL event focused on T1D and cadisegliatin is planned for the fourth quarter of 2026.
Cash and cash equivalents were $86.6 million at June 30, 2026, which vTv expects will fund operations through the anticipated CATT1 topline readout. For Q2 2026, R&D expenses were $8.8 million, G&A $5.2 million, and net loss attributable to shareholders was $13.1 million, or $1.05 per basic and diluted share. Six‑month 2026 revenue totaled $36.8 million. Stockholders’ equity increased to $78.6 million versus $64.4 million at December 31, 2025.